life scienc diagnost tool
drive industry-wid effici one acquisit
time initi buy pt
initi coverag buy rate pt
largest compani focus life scienc tool lst sector
consist track record deliv mid-singl digit organ revenu
growth low mid-teen ep growth capit scale
strong free cash flow gener bar signific downturn
multipl end market believ typic top bottom-
line growth profil sustain particularli given stabil
end market environ recent continu strength gener
provid ep leverag potenti posit impact
 tax reform share trade meaning discount
peer group lst compani price-to-earnings basi think
meaning upsid continu execut
great consolid one major consolid
lst industri tmo long-stand intern system drive
oper effici practic process improv ppi coupl
lead posit innov budget
propel grow portfolio success acquisit
 dionex phadia fei
deploy sinc expect deploy
capit next three year
accret ep return capit
diversifi end market provid stabil lt growth profil
biopharma revenu emerg market
revenu contribut high singl doubl digit revenu growth
histor tmo diversifi end market geograph
custom base ultim provid growth stabil lt
view
potenti caveat strong stock ralli peak multipl across
lst sector provid challeng comparison
valuat pt base price-to-earnings multipl discount
lst peer
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
anticip big surpris term guidanc given
compani consist perform also provid financi
model annual analyst day may exhibit
project compani kick organ revenu growth
target report revenu growth standpoint think could
variabl consensu attribut contribut
patheon acquisit complet august
bottom-lin think compani well posit anoth
ep growth includ accret patheon acquisit
adjust ep accret expect first full year exclud
potenti impact recent tax reform
tax front tax rate alreadi rel low
season tax team activ engag educ member
congress exampl think recent tax reform like
posit overal lot move part howev includ
reduct corpor tax rate vs previous favor
revenu lower tax repatri earn ou
like favor retent tax credit neutral near-term
potenti neg tmo custom post
capit amort sever year limit interest
deduct ebitda unfavor reinstat medic
devic tax start januari unfavor although believ
impact minim estim million annual save
two-year tax holiday put place etc look
upcom investor confer next week earn addit color
tax impact
risk buy rate pt includ
growth potenti across life scienc tool industri
signific slowdown demand thermo major custom
industrial/appli healthcare/diagnost market
signific slowdown emerg market growth particularli
china thermo product
price target base price-to-earnings multipl still
repres signific discount peer group life scienc tool
compani think potenti upsid given tmo ep
leverag capit deploy strategi also possibl multipl
expans opportun execut expect
contribut
report growth
acquisit increas
outlook fei
headwind mm
impact
contribut
increas outlook fei
headwind mm
bp expans
fx headwind bp
debt financ
acquisit complet
net expens mm
contribut
complet
headwind mm
impact
bp expans y/i
busi system fx-
acquisit expect
neutral margin
fx expect
slightli dilut margin
expect increas interest
rate
lower y/i due
adopt new rule stock
comp account reduc
tax rate bp
fx headwind
impact
acquisit account
growth
contribut
mm contribut
headwind mm
bp expans
patheon margin profil
lower dilut
overal om first
om expans bp
financ patheon
posit impact
benefit
headwind puerto
rico site offlin
due hurrican
mm due complet
recent equiti offer
fx headwind
fx headwind
fx headwind
impact
impact
acquisit account
share
mm dividend
mm share
alreadi complet jan
exhibit thermofish scientif compani snapshot compani report btigcompani descriptionthermofish scientif world largest life scienc tool compani thermoalso provid tool servic scientif research across multipl industri biopharma develop manufactur detect monitor applic environment food safeti industri end market thermoi headquart waltham histor perform non-gaap revenu mix ltm billionsrevenuerevenuegrowth y/yconsum america govern healthcar appli marketstot address
exhibit thermofish scientif compani snapshot compani report btigmanagementmarc casper presid ceo director kendrolaboratori product dade behr bain board truste brigham women vice chair us-china busi council board patrick durbin presid specialti diagnost covanc gregori herrema presid custom channel ge borg warner chemic board advisor alda sy jafri presid region ge glaxo michel lagard presid pharma servic patheon partner philip electron frederick loweri presid life scienc solut laboratori product maytag shine presid arthur anderson mark stevenson appli biosystem richard spoor svp global busi servic bayer consum health merck nokia qp group ge light andrew thomson presid emea roch diagnost dade behr stephen williamson cfo honeywel pwc board directorsjim manzi chairman stonegatecapit lotu develop director titbitpt continent grain gather brigham women nelson chai warranti group merril lynch nyse euronext archipelago hold martin harri md medic school ut austin cleveland clinic director tyler jack phd mit hhmi director judi lewent merck director glaxosmithklin thoma lynch te connect tyco engin product servic motorola director william parrett deloitt touchetohmatsu director blackston group eastman kodak ub director lar srensen novo nordisk board bertelsmann carlsberg svenskacellulosaaktiebolaget scott sperl thoma partner aenea group bcg director iheartmediaand madison squar garden compani elain ullian boston medic center bu medic center hospit faulkner hospit director dion weisler hp inc busi segment base result lab product serviceslif scienc solutionsspecialti diagnost productinstru regionsno america america america america businessesresearch safeti market channel product scienc mass spec structur analysi analysi market channel patholog mfg organ revenu growth adj oper margin expans bp oper accret acquisit bp cagrannu adj oper incom growth rate exclud potenti tax reform impact adj ep cagrfre cash flow convers adj net incomedeploy capit bolt-on acquisit share buyback dividendsleverag averag year-end debt/ebitdaadj bp compound-annual-growth-rate without reach
fiscal year end dec million except per share scienc diagnost product revenu profit profit develop expens incom non-oper non-oper expens incom tax incom incom analysiscost revenu margin gener administr develop margin tax margin growthlif scienc diagnost product bpssg incom bpsnet incom compani report btig estim
btig cover compani mention report
appendix analyst certif import disclosur
